| 7.99 -0.15 (-1.84%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.26 | 1-year : | 11.99 |
| Resists | First : | 8.78 | Second : | 10.26 |
| Pivot price | 7.79  |
|||
| Supports | First : | 7.09 | Second : | 6.05 |
| MAs | MA(5) : | 8.34 |
MA(20) : | 7.49 |
| MA(100) : | 8.6 |
MA(250) : | 6.54 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 86 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 12.25 | Low : | 2.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENGN ] has closed below upper band by 40.1%. Bollinger Bands are 19.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.2 - 8.25 | 8.25 - 8.29 |
| Low: | 7.77 - 7.84 | 7.84 - 7.88 |
| Close: | 7.91 - 8 | 8 - 8.07 |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Tue, 21 Apr 2026
Wells Fargo Maintains EnGene Holdings(ENGN.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Sat, 18 Apr 2026
enGene Holdings (ENGN) Stock: Overpriced? (At Lows) 2026-04-18 - Attention Driven Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Thu, 09 Apr 2026
Detalimogene program drives enGene (ENGN) shift to Therapeutics focus - Stock Titan
Tue, 07 Apr 2026
enGene Announces Name Change to enGene Therapeutics Inc. - Yahoo Finance
Tue, 07 Apr 2026
enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch - TipRanks
Tue, 07 Apr 2026
enGene (NASDAQ:ENGN) Shares Up 5.2% - Here's Why - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 98 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 1,240 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.7 % |
| Return on Equity (ttm) | -46.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -102 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -3.56 |
| PEG Ratio | 0 |
| Price to Book value | 1.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|